USE OF BIFIDOBACTERIUM ANIMALIS SUBSP. LACTIS SG105 TO DELAY AGING

Abstract

USE OF BIFIDOBACTERIUM ANIMALIS SUBSP. LACTIS SG105 TO DELAY AGING The invention relates to a use of Bifidobacterium animalis subsp. lactis SG105 to delay aging. Administering an effective amount of Bifidobacterium animalis subsp. lactis SG105 or a composition containing Bifidobacterium animalis subsp. lactis SG105 to an individual reduces the amount of peroxides, and therefore oxidative stress, in the individual's body to prevent oxidative damage to cells or tissues, thus producing an anti-aging effect and delaying diseases or symptoms caused by aging.

Description

Title of the invention: USE OF BIFIDOBACTERIUM ANIMALIS SUBSP. LACTIS SG105 TO DELAY AGING BACKGROUND OF THE INVENTION

[0001] 1. Technical field

[0002] The present invention relates to a second use of a probiotic strain. More particularly, the invention relates to a use of Bifidobacterium animalis subsp. lactis SG105 to delay aging.

[0003] 2. Description of the related technique

[0004] Improvements in medical care and quality of life have led to an annual increase in the average life expectancy of human beings; consequently, the elderly population continues to grow worldwide. According to statistics, people aged 65 and over in 2022 represented 10% of the world's population that year, and the United Nations has projected that this percentage will reach 16% by 2050. Given the effects of aging on human health and social protection systems, the question of how to delay aging has not only become an important issue in all countries, but is also one that can create business opportunities, particularly in the pharmaceutical, biotechnology, cosmetics and personal care, and health food industries.

[0005] Research data has shown that the global market for anti-aging products is projected to reach $93.1 billion by 2027, with nutritional supplements and health foods holding the largest share, followed by the treatment and prevention of age-related diseases. With the biotechnology and medical industries now focused on developing anti-aging products and technologies, it is important that each manufacturer involved finds ways to produce safe and effective anti-aging products. BRIEF SUMMARY OF THE INVENTION

[0006] The main objective of the present invention is to propose a use of Bifidobacterium animalis subsp. lactis SG105 to delay aging such that the administration of Bifidobacterium animalis subsp. lactis SG105 or of a composition containing Bifidobacterium animalis subsp. lactis SG105 to an individual effectively contributes to maintaining the individual's figure, memory and physical appearance.

[0007] The secondary objective of the present invention is to propose a use of Bifi- Dobacterium animalis subsp. lactis SG105 to delay aging, Bifido-bacterium animalis subsp. lactis SG105 being a probiotic strain with anti-aging activity and no side effects on an individual and not causing dependence on a substance after long-term consumption.

[0008] To achieve the aforementioned objectives, the present invention discloses a use of Bifidobacterium animalis subsp. lactis SG105 in the preparation of an anti-aging and / or antioxidant composition, Bifidobacterium animalis subsp. lactis SG105 having been filed with the German Collection of Microorganisms and Cell Cultures GmbH (Deutsche Sammlung von Mikroorganismen und Zellkulturen, or DSMZ), the filing number being DSM 34662 and the filing date being June 8, 2023.

[0009] The anti-aging composition may be a food product, a nutritional supplement, a drug or a body care product.

[0010] The present invention also discloses a use of Bifidobacterium animalis subsp. lactis SG105 in the preparation of a composition for memory enhancement, Bifidobacterium animalis subsp. lactis SG105 having been filed with the German Collection of Microorganisms and Cell Cultures GmbH (Deutsche Sammlung von Mikroorganismen und Zellkulturen, or DSMZ), the filing number being DSM 34662 and the filing date being June 8, 2023. The composition for memory enhancement may be a food product, a nutritional supplement or a drug.

[0011] The composition according to the invention may be a food, a personal care product for external use, a nutritional supplement, or a medicinal product. The composition may be prepared in various dosage forms, such as drops, powder, tablets, and capsules, depending on the individuals to whom the composition will be administered, the method of administration, and the method of consumption. The composition may also include additional ingredients such as an excipient, a sweetener, and a vehicle.

[0012] When prepared as a nutritional supplement, the composition comprises an effective amount of Bifidobacterium animalis subsp. lactis SG105 and an ingredient acceptable in food. When prepared as a medicinal product, the composition comprises an effective amount of Bifidobacterium animalis subsp. lactis SG105 and a pharmaceutically acceptable vehicle.

[0013] Bifidobacterium animalis subsp. lactis SG105 is effective in enhancing the activity of antioxidant enzymes (e.g., superoxide dismutase and catalase) in an individual's body. Therefore, when administered to an individual, the aforementioned composition effectively eliminates or reduces The amount of peroxides in the body helps prevent cell damage from oxidative stress, thereby delaying aging and, consequently, age-related diseases and symptoms. In other words, the composition described here can be used to combat aging, delay memory loss, improve learning abilities, reduce cellular damage, maintain physical appearance, and prevent premature aging.

[0014] BRIEF DESCRIPTION OF THE DIFFERENT VIEWS OF THE FIGURES

[0015] [Fig.1] shows the result of the evaluation of the aging index of the mice in each group in Example 2.

[0016] [Fig.2] shows the result of the one-trial passive avoidance test of mice in each group at the 24th hour following learning and training.

[0017] [Fig.3] shows the result of the active avoidance test of mice in each group the Day two of the test.

[0018] [Fig.4] shows the result of the analysis of superoxide dismutase activity in the livers of mice in each group.

[0019] [Fig. 5] shows the result of the analysis of catalase activity in the liver of mice in each group. DETAILED DESCRIPTION OF THE INVENTION

[0020] The present invention discloses a use of Bifidobacterium animalis subsp. lactis SG105 for delaying aging. Since Bifidobacterium animalis subsp. lactis SG105 can increase the activity of superoxide dismutase and catalase, administering an effective amount of Bifidobacterium animalis subsp. lactis SG105 or a composition containing Bifidobacterium animalis subsp. lactis SG105 to an individual reduces the amount of peroxides, and therefore oxidative stress, in the individual's body to prevent oxidative damage to cells or tissues, thus producing an anti-aging effect and delaying diseases or symptoms caused by aging, such as memory loss, reduced learning ability, and an aged physical appearance.

[0021] Bifidobacterium animalis subsp. lactis SG105 has been filed with the German Collection of Microorganisms and Cell Cultures GmbH (Deutsche Sammlung von Mikroorganismen und Zellkulturen, or DSMZ). The filing number is DSM 34662 and the filing date is June 8, 2023.

[0022] The term "administer" refers to giving a substance such as a drug to an individual. The method of administration is not limited to oral administration, and it is possible to administer a substance or drug at the same time as a regular food or food composition is provided to be consumed.

[0023] The term "composition" means a substance such as a food product, nutritional supplement or animal feed which contains Bifidobacterium animalis subsp. lactis SG105 as the main active ingredient, and which can be prepared in various dosage forms such as powder, tablets, liquid and capsules, depending on the individuals to whom the composition will be administered, the dosage of administration and the method of administration.

[0024] The term "effective quantity" or "effective dose" refers to a dose that produces the intended effect of the present invention on an individual, the dose being able to vary depending on the individual to whom the substance in question is administered.

[0025] The term "aging" refers to changes in the physiological conditions, body or physical appearance of an individual due to the increase in their age, such as wrinkles, decreased vigor, memory loss, increased curvature of the spine, swelling of the eyelids, tendency to fatigue, rough hair, hair loss, skin ulcers, decreased hair shine and reduced antioxidant capacity.

[0026] The terms "anti-aging" or "resisting aging" refer to reducing the rate of aging or the onset of age-related symptoms, or to improving or strengthening the condition of the body or the physical appearance of an individual after it has been degraded by aging.

[0027] The technical characteristics of the present invention and their intended effects are detailed below with reference to examples and the attached drawings.

[0028] The Bifidobacterium animalis subsp. lactis SG105 used in the following examples has been deposited with the German Collection of Microorganisms and Cell Cultures GmbH. The deposit number is DSM 34662 and the deposit date is June 8, 2023.

[0029] The animals used in the following examples are SAMP8 mice. This strain of mouse has a short lifespan and has been recognized in the technical field to which the present invention relates as a suitable experimental animal model for use in studies relating to the delay of aging and reproductive functions.

[0030] The single-trial passive avoidance test and the active avoidance test described in the following examples are methods commonly used in the technical field to which the present invention relates for testing an individual's learning ability and memory.

[0031] Example 1: Preparation of a probiotic sample

[0032] Bifidobacterium animalis subsp. lactis SG105 was cultured and propagated in a liquid carbon and nitrogen-based culture medium to produce a liquid bacterial, from which a bacterial sludge was then separated by centrifugation. The bacterial sludge was subjected to preparation processes such as freeze-drying and grinding, and a sample of Bifidobacterium animalis subsp. lactis SG105 was obtained as a result. Example 2: Animal testing

[0033] Several three-month-old SAMP8 mice were randomly divided into two groups: a control group serving as a reference for comparing the aging states of the two groups, and a Bifidobacterium animalis subsp. lactis SG105 group. The control group was tube-fed with double-distilled water (ddH2O), and the Bifidobacterium animalis subsp. lactis SG105 group was fed the Bifidobacterium animalis subsp. lactis SG105 sample (1109 colony-forming units (CFU) / mouse / day), with tube feeding performed once daily. Other rearing conditions were the same for both groups. The test lasted 13 weeks, during which not only were the mice's body weight and the amounts of food and water they consumed recorded, but predetermined aging indices were also assessed.

[0034] Example 3: Results of the evaluation of aging indices in mice

[0035] The following aspects of physical appearance, condition of the eyes and deviation of The spines of the mice in each group were assessed by observation and touch: hair gloss, hair stiffness, hair loss, skin ulcers, mucus around the eyes or periophthalmic lesions, and lordosis / kyphosis of the spine (examined by visual inspection and touch). The result of the assessment of each aspect was classified into five levels and given a score of 0, 1, 2, 3, or 4, where the higher the score, the more severe the aging phenomenon. The scores for all aspects were summed and the average was calculated for each group, and the results are presented in [Fig. 1].

[0036] According to the results of [Fig. 1], the mean sum of the aging index scores for the Bifidobacterium animalis subsp. lactis SG105 group was 3.63 ± 0.24, which is significantly lower than that of the control group (6.25 ± 0.55). This indicates that Bifidobacterium animalis subsp. lactis SG105 is capable of suppressing the manifestations of aging; in other words, administering an effective amount of Bifidobacterium animalis subsp. lactis SG105 or a composition containing Bifidobacterium animalis subsp. lactis SG105 to an individual can produce an anti-aging effect or help resist the symptoms of aging.

[0037] Example 4: Single-trial passive avoidance test

[0038] A 35 (Width) x 17 (Depth) x 20 (Height) cm³ aluminum shuttle-type avoidance cage (Coulboum Instruments, model E10-15) was used for the test. The lower part of the aluminum shuttle-type avoidance cage was equipped with ge The cage was divided into two compartments by a central aluminum plate. This aluminum plate was fitted with a 7.5 cm² (Width x 6.5 cm²) automatic guillotine door (Coulbourn Instruments, model E10-15GD). One of the compartments was illuminated, while the other was unlit and covered with black panels to create a dark compartment.

[0039] The test was conducted as follows. With the guillotine door closed, a mouse was placed in the illuminated compartment. After 10 seconds, the guillotine door was automatically opened to allow the mouse to move freely between the compartments. Once the mouse entered the dark compartment, the guillotine door was closed, and 5 seconds later, the mouse received three consecutive 0.5 pA electric shocks at 5-second intervals, each shock lasting 0.5 seconds. If the mouse did not enter the dark compartment within 180 seconds, the test ended automatically. The first day was used for learning and training, and the electric shocks were therefore administered as described above. After the learning and training period, no electric shocks were administered.The test continued until 24 hours after learning and training, and during this hour the time that the mice in each group remained in the illuminated compartment (i.e., the latency time) was recorded, as shown in [Fig. 2].

[0040] According to the results in [Fig. 2], the mice in the Bifidobacterium animalis subsp. lactis SG105 group had a latency of 67.63 ± 2.46 seconds, which is significantly longer than that of the control group (46.25 ± 1.65 seconds). The results in [Fig. 2] indicate that administration of Bifidobacterium animalis subsp. lactis SG105 effectively improves an individual's learning capacity and memory. Example 5: Active Avoidance Test

[0041] An aluminum shuttle-type avoidance cage measuring 35 (Width) x 17 (Depth) x 20 (Height) cm³ was divided into two compartments, between which was a guillotine door measuring 7.5 (Width) x 6.5 (Depth) cm². When the guillotine door was open, the two compartments communicated with each other. The bottom of the shuttle cage was fitted with parallel metal rods arranged at 1 cm intervals and connected to a current source.

[0042] The mice in each group were tested as follows. A mouse was placed in one of the compartments and allowed to adapt to the environment for 10 seconds. Then, a conditioned stimulus (CS) consisting of light and sound was provided for 10 seconds. If the mouse subjected to the light stimulus and If the auditory stimulus remained in the same compartment, an unconditioned stimulus (UCS) consisting of a 0.3 mA electric shock for five seconds was applied once to the mouse; if the mouse exposed to the visual and auditory stimulus entered the other compartment, no electric shock was applied. Each mouse in each group underwent four trials per day for four consecutive days, each trial comprising five sessions of UCS-UCS administered at 15- to 20-minute intervals. The results of the active avoidance test on the second day of the test were recorded and are presented in [Fig. 3].

[0043] According to the results of [Fig. 3], the number of successful active avoidances of mice in the Bifidobacterium animalis subsp. lactis SG105 group was 12 ± 0.78, while the number of successful active avoidances of mice in the control group was 10.13 ± 0.61, a number that is significantly lower than that of the Bifidobacterium animalis subsp. lactis SG105 group. The results of [Fig. 3] further demonstrate that Bifidobacterium animalis subsp. lactis SG105 improves the loss of learning and memory capacity caused by aging; in other words, administration of Bifidobacterium animalis subsp. lactis SG105 improves the learning capacity and memory of an elderly person.

[0044] Example 6: Superoxide dismutase (SOD) activity test

[0045] 0.1 ml of liver tissue fluid was collected from each mouse in each The group from Example 2 was mixed with 400 µl of ddH2O, thoroughly stirred, and left to stand at 4°C for 15 minutes before being centrifuged. 10 µl of the supernatant were taken, mixed with 490 µl of sample dilution agent, thoroughly stirred, and then tested. The test results are shown in [Fig. 4].

[0046] The results of [Fig. 4] show that after providing the Bifidobacterium animalis subsp. lactis SG105 sample to aged SMAP8 mice for 13 weeks, SOD activity in the liver reached 12992 ± 231 units / g of protein, which is significantly higher than the SOD activity in the liver of the control group (8735 ± 325 units / g of protein). The results of [Fig. 4] indicate that Bifidobacterium animalis subsp. lactis SG105 has antioxidant activity, i.e., that the administration of Bifidobacterium animalis subsp. lactis SG105 or a composition containing Bifidobacterium animalis subsp. lactis SG105 in an individual helps reduce oxidative stress in the individual's body to prevent oxidative damage to cells, thus producing an anti-aging effect or delaying age-related diseases. Example 7: Catalase (CAT) Activity Test

[0047] A homogeneous liquid was obtained from the liver of each mouse in each group of Example 2 and was centrifuged at 4°C and 10,000 µg for five minutes. 10 µl of the supernatant were taken and diluted 1000-fold with 50% phosphate buffer mM to produce a diluted test liquid. Two mL of the diluted test liquid were added to 1 mL of 30 mM hydrogen peroxide and thoroughly mixed immediately before a spectrophotometer was used to determine the change in absorbance at 240 nm and 25°C in one minute. Catalase activity in the liver of each group of mice was calculated from the corresponding changes in absorbance, and the results are shown in [Fig. 5].

[0048] According to the results of [Fig. 5], the CAT concentration in the liver of mice in the Bifidobacterium animalis subsp. lactis SG105 group was 66.37 ± 2.08 nmol / min / ml, and the CAT concentration in the liver of mice in the control group was 50.0 ± 1.35 nmol / min / ml, a concentration that is significantly lower than that of the Bifidobacterium animalis subsp. lactis SG105 group. The results indicate that Bifidobacterium animalis subsp. lactis SG105 enhances CAT activity; in other words, administration of Bifidobacterium animalis subsp. lactis SG105 or a composition containing Bifidobacterium animalis subsp. lactis SG105 to an individual helps prevent the individual's tissues or cells from being damaged by excessive peroxides, thus producing an antioxidant and anti-aging effect and preventing associated diseases.

Claims

Demands

1. Use of Bifidobacterium animalis subsp. lactis SG105 in the preparation of an anti-aging and / or antioxidant composition, Bifidobacterium animalis subsp. lactis SG105 having been filed with the German Collection of Microorganisms and Cell Cultures GmbH (Deutsche Sammlung von Mikroorganismen und Zellkulturen, or DSMZ), the filing number being DSM 34662 and the filing date being June 8, 2023.

2. Use of Bifidobacterium animalis subsp. lactis SG105 in the preparation of an anti-aging and / or antioxidant composition according to claim 1, the anti-aging composition being a food product, a nutritional supplement, a medicinal product or a personal care product.

3. Use of Bifidobacterium animalis subsp. lactis SG105 according to claim 1 in the preparation of a composition for memory enhancement.

4. Use of Bifidobacterium animalis subsp. lactis SG105 in the preparation of a composition for memory enhancement, according to claim 3, the composition for memory enhancement being a food product, a nutritional supplement or a drug.

5. Anti-aging and antioxidant composition, comprising an effective amount of Bifidobacterium animalis subsp. lactis SG105, Bifidobacterium animalis subsp. lactis SG105 having been filed with the German Collection of Microorganisms and Cell Cultures GmbH (Deutsche Sammlung von Mikroorganismen und Zellkulturen, or DSMZ), the filing number being DSM 34662 and the filing date being June 8, 2023.

Images